Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Mom warns of Christmas gift hazard as daughter recovers in hospital - 27 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- 3Why is the Artemis 2 rocket launch different from all other rocket launches?
- 4The 10 Most Famous Works of art Ever
- 5No respite for German economy as experts slash forecast over Iran war
- Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
- Italy Brings In New Measures In 2026 To Tackle Overtourism
- VPN Administrations for Online Protection
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- L.A.'s most famous midcentury home, the Stahl House, is on the market for the 1st time, at $11K per square foot: See inside
- 5 Instructive Toy Brands for Youngsters
- Unwind: Four Extraordinary Spa Resorts On the planet
- Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips
